Co-incubation of Teclistamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Teclistamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.279 nM.

Teclistamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Teclistamab bound to huCD3e-jurkat cells, and the EC50 was 1.774 nM.

Teclistamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Teclistamab bound to huBCMA-HEK293 cells, and the EC50 was 2.421 nM.

Teclistamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Teclistamab bound to huBCMA-ECD-His , and the EC50 was 0.106 nM.

The purity of Anti-CD3 & BCMA Reference Antibody (Teclistamab) is more than 97.30%, determined by SEC-HPLC.

Anti-CD3 & BCMA Reference Antibody (Teclistamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.

The detected molecular weight of Anti-CD3 & BCMA Reference Antibody (Teclistamab) is 143.38 kDa.